InsidersTradesSigma
Track the CAMP4 Therapeutics Corporation share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €260.4m. The latest transaction was disclosed on 19 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Daniel Tardiff. The full history is openly available.
Analysts rate CAMP4 Therapeutics Corporation Strong Buy (bullish), based on 6 analysts. Average price target: US$9.92.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
CAMP4 Therapeutics Corporation is a company focused on developing innovative therapies for genetic diseases. It employs biology-based approaches to design targeted treatments.